Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)

Document first published:
Page updated:
Topic:
,
Publication type:

This policy document outlines the arrangements for funding of treatment for relapsed and refractory mantle cell lymphoma (all ages).